Other equities analysts also recently issued reports about the company. Berenberg Bank reiterated a buy rating and set a £115 ($140.91) price objective on shares of AstraZeneca in a research report on Tuesday, July 26th. Credit Suisse Group set a £110 ($134.79) price objective on AstraZeneca in a report on Tuesday, June 7th. JPMorgan Chase & Co. set a £120 ($147.04) price target on AstraZeneca in a research report on Wednesday, July 13th. UBS Group set a £101 ($123.76) price objective on shares of AstraZeneca in a research report on Tuesday, June 14th. Finally, Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a research report on Friday, July 22nd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, AstraZeneca currently has a consensus rating of Buy and an average price target of £106.13 ($130.04).
AstraZeneca Stock Performance
LON:AZN opened at £106.62 ($130.65) on Monday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 90.06. The firm has a market capitalization of £165.21 billion and a price-to-earnings ratio of -181.33. The firm’s fifty day simple moving average is £106.02 and its 200 day simple moving average is GBX 9,951.88. AstraZeneca has a twelve month low of GBX 8,029 ($98.38) and a twelve month high of £112.90 ($138.34).
AstraZeneca Cuts Dividend
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- There Are Different Types of Stock To Invest In
- PayPal Continues To Struggle As Competition Increases
- Is Starbucks Shooting For The Moon?
- Two High-Yield Deep-Values You Shouldn’t Ignore
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.